Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 850 participants.
Also called NCT06014112
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 850 participants
- Registry
-
NCT06014112
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT06014112. Allocation not applicable; no masking; primary purpose prevention. Start 2023-11-06 (actual); primary completion 2028-05-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS
- Acronym
- FREESCA
- Condition
- Acute Coronary Syndrome
- Condition
- Continuous Glucose Measurement
- Condition
- Glycemic Variability
- Condition
- Cardiovascular Event
- Intervention (Device)
- Freestyle Libre Pro iQ
- Lead sponsor
- University Hospital, Montpellier
Record details
- Record id
cardio:ct-nct06014112- Content hash
86ee420fc740763494a7572583f4494f895830a26a1391a6da60d45b56429e5a